HalioDx Overview

  • Founded
  • 2014
  • Status
  • Private
  • Employees
  • 165
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $21M
Latest Deal Amount
  • Investors
  • 9

HalioDx General Information


Developer of a line of immunologic scoring tests intended to investigate the immune response within the tumor environment. The company's tests are developed using a proprietary set of Immune biomarkers, advanced image analysis technologies to precisely measure the immune reaction in and around the tumor, enabling clinicians to determine the degree of severity of the patient's disease and to predict response to treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Primary Office
  • Luminy Biotech Entreprises
  • 163 Avenue de Luminy, Marseille Cedex 9
  • 13288 Marseille
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HalioDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 10-Dec-2018 $21M 0000 000.00 Completed Generating Revenue
2. Buyout/LBO (MBO) 15-Jun-2015 00.00 000.00 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view HalioDx’s complete valuation and funding history, request access »

HalioDx Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ABSA 00,000 0000.00 0000.00 00 0000.00 00.000
ADP B 00,000 0000.00 0000.00 00 0000.00 00.000
To view HalioDx’s complete cap table history, request access »

HalioDx Executive Team (7)

Name Title Board Seat Contact Info
Vincent Fert Co-Founder, President, Chief Executive Officer & Chairman
Jérôme Galon Ph.D Co-Founder, Chairman of Scientific Advisory Board & Consultant
Leïla Boujadaïne Director, Finance
Stéphane Debono Executive Vice President, Diagnostics BU & Board Member
Corinne Danan Executive Vice President, Partnerships BU & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

HalioDx Board Members (13)

Name Representing Role Since
Audrey Boccadifuoco Self Board Observer 000 0000
Bervin Bouani Sham Innovation Santé Board Member 000 0000
Christophe Somaini Amundi Private Equity Funds Board Observer 000 0000
Corinne Danan HalioDx Executive Vice President, Partnerships BU & Board Member 000 0000
Ekaterina Smirnyagina Ph.D Capricorn Partners Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

HalioDx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HalioDx Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Amundi Private Equity Funds PE/Buyout Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Capricorn Partners Venture Capital Minority 000 0000 000000 0
BNP Paribas Asset Management Asset Manager Minority 000 0000 000000 0
MI Care Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »